Control of protein activity in living cells can reveal the role of spatiotemporal dynamics in signaling circuits. Protein analogs with engineered allosteric responses can be particularly effective in the interrogation of protein signaling, as they can replace endogenous proteins with minimal perturbation of native interactions. However, it has been a challenge to identify allosteric sites in target proteins where insertion of responsive domains produces an allosteric response comparable to the activity of native proteins. Here, we describe a detailed protocol to generate genetically encoded analogs of proteins that can be allosterically controlled by either rapamycin or blue light, as well as experimental procedures to produce and test these analogs in vitro and in mammalian cell lines. We describe computational methods, based on crystal structures or homology models, to identify effective sites for insertion of either an engineered rapamycin-responsive (uniRapR) domain or the light-responsive light-oxygen-voltage 2 (LOV2) domain. The inserted domains allosterically regulate the active site, responding to rapamycin with irreversible activation, or to light with reversible inactivation at higher spatial and temporal resolution. These strategies have been successfully applied to catalytic domains of protein kinases, Rho family GTPases, and guanine exchange factors (GEFs), as well as the binding domain of a GEF Vav2. Computational tasks can be completed within a few hours, followed by 1-2 weeks of experimental validation. We provide protocols for computational design, cloning, and experimental testing of the engineered proteins, using Src tyrosine kinase, GEF Vav2, and Rho GTPase Rac1 as examples.
Introduction
Cells precisely coordinate signal transduction in space and time using complex and dynamic protein networks. Understanding and controlling such tight regulation, especially for rapid behaviors such as cell motility, necessitates approaches that allow manipulation of signaling with high temporal and/or spatial resolution in living cells. Because many proteins function in more than one subcellular region, it is often valuable to control the activity of an intact protein, rather than targeting a protein fragment with specific activity to a particular subcellular location [1] [2] [3] . Engineering allostery offered a way to control protein activity without disrupting native interactions of the target protein, and it provided kinetic control. The unimolecular rapamycin-regulatable (uniRapR) domain was inserted at a site allosterically coupled to the active site. This perturbed the active site, except when the uniRapR domain was bound to rapamycin. The same allosteric site was used to insert the phototropin LOV2 domain, which destabilized and thereby inactivated the protein upon blue light absorption. For example, by using rapamycin activation, we could activate different Src family isoforms, determining their specific roles even though their sequences and structures were closely related 3 . In contrast to genetic manipulation, which would have allowed compensation and upregulation of other members of the Src family, we could study cells immediately after altering the function of individual family members. Furthermore, by activating the kinase at precise times during trafficking, we could dissect out different roles of its target proteins [1] [2] [3] . As in other structure-based computational design approaches, our protocol requires knowledge of the target protein's structure, or at least the structure of homologous proteins, to insert elements that respond to artificial stimuli. Combinatorial approaches, not addressed here, can identify sites that are missed due to the limits of computational methods [4] [5] [6] , but the design and implementation of the required assays can be challenging. For the method described here, the choice of an inducer-ligand or light-must be considered carefully, as ligand-based control is currently irreversible and takes place over seconds, as rapamycin diffuses into the cell. By contrast, light provides reversibility, higher temporal and spatial resolution, and adjustable kinetics, but requires more complex approaches to readily reach deep into tissues. We illustrate the critical steps required to alter a target protein so that it responds allosterically to light or rapamycin analogs, including non-immunosuppressive analogs (rapalogs) that do not interact with the mTOR pathway 7, 8 ( Fig. 1 ). Rapamycin can bind to the regulatory domain of the mTOR complex, affecting cell function. The FKBP-rapamycin binding (FRB) unit of the uniRapR domain carries a T2098L mutation, which increases the affinity for rapamycin analogs. We describe reversible protein photoinhibition and weakly reversible bimolecular (RapR) or unimolecular (uniRapR) rapamycininduced activation (Fig. 2) . We have also accomplished reversible photoactivation through light control of autoinhibitory domains 1 .
Strategies to make genetically encoded, allosterically controlled proteins
Protein activation by rapamycin: RapR and uniRapR
In the presence of the small molecule rapamycin, the 12-kDa FK506 binding protein (FKBP12) interacts with the 11-kDa protein FRB. This interaction has been exploited to control the localization of proteins by fusing the target protein to one member of the interacting pair, and a cellular targeting sequence to the other 2,7,9-11 . Addition of rapamycin, which is cell permeable, results in localization of the target protein to a specific cellular compartment. In the approach described here, an insertable truncated FKBP12 (iFKBP) is inserted into the target proteins to control their conformation 2, [10] [11] [12] . iFKBP was created by removing the first 20 amino acids from the N terminus of FKBP12, bringing the N and C termini close together (~7 Å apart) and thereby enabling iFKBP insertion into target proteins without greatly changing the spacing across insertion sites ( Fig. 2; ref. 10 ). Because the iFKBP domain is predominantly unstructured without rapamycin, as shown by molecular dynamics simulations 10 , insertion of iFKBP decreases the stability of the target protein structure and thereby results in inactivation of the target protein. Once iFKBP binds rapamycin and FRB, it becomes predominantly structured, resulting in activation of the target protein 10 . This approach requires the co-expression of FRB, so heterogeneity in expression levels can result in differences in activation level from cell to cell. To reduce this complexity, a unimolecular version of this system was developed by fusing a circularly permutated FRB (an engineered form of FRB with different amino acid connectivity but with a similar 3D structure) to the iFKBP structure 13 . This fusion protein was named the uniRapR domain, and it enabled ready generation of single-chain rapamycin-sensitive proteins 1, 13 . Rapamycin may have side effects in cells, especially during long-term application, as it is an mTOR complex inhibitor. However, inert rapamycin analogs that interact predominantly with a mutant form of exogenous FKBP12, iFKBP, and uniRapR enable specific activation of the target proteins 7, 8, 10, [13] [14] [15] . Steps 1-7 describe computational approaches to identify sites on the target (host) protein for insertion of domains that respond to light or rapamycin (sensory domains). Steps 8-13 describe cloning of the designed constructs, and
Step 14A(i)-14B(x) describes testing of the engineered constructs (plasmids with the blue and red inserts) or their controls (blue insert) using biochemical assays.
Step 14C covers testing of the engineered constructs or controls using FRET biosensors (the plasmid with the yellow insert) through high-content imaging.
Steps 15-18 address live-cell imaging and quantification of morphology parameters such as membrane protrusion (green) and retraction (red). Rap, rapamycin.
Activation results from a specific protein-protein interaction or occurs at a selected subcellular site: RapR-TAP Using RapR-TAP (rapamycin-regulated targeted activation of proteins), it is possible to cause an activated protein to interact only with a specific downstream ligand (Fig. 1) . In RapR-TAP, iFKBP is inserted into the protein to be activated, and FRB is attached to the downstream target. Activation can only occur when the target protein and the specific downstream partner are brought together in the presence of rapamycin. RapR-TAP can also be used to activate a protein at selected subcellular sites if FRB is tagged with a localization sequence while iFKBP is inserted into the protein targeted for allosteric control. Using this strategy, it was shown that the effects of the tyrosine kinase Src are substantially different in the cytosol versus the plasma membrane 2 , and that specific events downstream of Src can be attributed to Src interaction with its substrate focal adhesion kinase (FAK) or to Crk-associated substrate (p130Cas) 2 .
Photoactivation and photoinhibition with LOV2
The LOV-sensing domain (LOV2, 12 kDa) is used by plants, microalgae, fungi, and bacteria to sense environmental cues. Its cofactor flavin, seated in the Per-Arnt-Sim (PAS) subdomain of LOV2, absorbs light efficiently between 300 and 500 nm, with maximal effect at 450 nm. Upon light absorption, the flavin forms a covalent bond with a cysteine residue (C450) in the PAS domain 16, 17 . This leads to a conformational change that propagates from the PAS domain to the C-terminal Jα helix and to a short N-terminal helix, resulting in distortion and the unfolding of the Jα helix of LOV2 (ref. 18 ). This light-induced allosteric regulation has been used for various modes of protein control. For example, a photoactivatable analog of the small GTPase Rac1 (PA-Rac1) was generated by fusing the C terminus of LOV2 to the N terminus of Rac1 (ref. 19 ). The crystal structure of PA-Rac1 revealed that in dark conditions, LOV2 sterically blocked the Rac1 active site, but the active site was exposed when the Jα helix was unwound upon illumination 18 . PA-Rac1 has been used to study protein
RapR uniRapR
RapR-TAP Heterodimerization of iFKBP with co-expressed FRB is induced by addition of rapamycin (pink circle) to the medium, leading to activation of the target protein and productive interaction with downstream targets (P). Typically, constitutively active proteins are used so that activity is solely controlled by the user. b, The single-chain unimolecular version of this approach, called uniRapR, does not require co-expression of FRB, as the inserted domain (U) is a fusion of iFKBP and FRB. c, RapR-TAP enables allosteric activation of the target protein in a specified subcellular region, or when it is interacting specifically with one downstream target. Here, iFKBP is inserted into the target, and the FRB domain required for activation is fused to a subcellular targeting sequence (left) or to the specific target protein (right). d, In protein photoactivation, the LOV2 domain (L) is fused to the target protein, where it sterically blocks the active site. Blue light induces a LOV2 conformational change that reversibly uncovers the active site. e, In allosteric photoinhibition, LOV2 is inserted at a site where it allosterically perturbs the active site only in the light. f, A structural model of uniRapR 13 bound to rapamycin (top) and the LOV2 domain from the crystal structure of PARac1 (PDB ID 2WKP). The close proximity of the N and C termini of LOV2 and of the iFKBP portion of the uniRapR domain enables successful insertion into surface loops and subsequent allosteric regulation. hv, light.
function in a wide variety of systems and animals: cellular protrusions in fibroblasts 19 , collective cell migration in Drosophila
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, and learning and memory in mice [21] [22] [23] . The LOV2 domain has been used in a variety of designs to activate proteins, including caspase-7 (ref. 24 ), stromal interaction molecule 1 (Stim1; ref. 25 ), endonuclease PvuII 26 , ornithine decarboxylase-like degradation sequence 27 , formin mDia 28, 29 , and DNA-binding proteins 30, 31 . Because the termini of LOV2 are relatively close to each other (within~15 Å) in the dark state 18 , LOV2 can be inserted into the surface of target proteins through direct insertion into exposed loops, sometimes with replacement of a few amino acids in the exposed loop. We have shown that surface insertion of LOV2 into various types of proteins, including Src kinase and Rho family GEFs and GTPases, can provide light-induced inhibition of their activity 1 . We computationally identified surface loops that were 'tight' (controlling the proximity of two internal structured units, e.g., the loop connecting interacting antiparallel helices or strands of a β-pleated sheet), were not evolutionarily conserved, and were allosterically coupled to the active site. By inhibiting autoinhibitory domains, we could also achieve activation. We applied this approach to several protein domains, including the catalytic domain of a kinase, the catalytic Dbl homology (DH) domain of Rho GEFs, the autoinhibitory domain of GEF Vav2, and the catalytic domain of Rho GTPases 1 .
Comparison with other methods
There are multiple genetically encoded strategies for controlling protein activity with precise kinetics. Because many proteins function at specific subcellular regions, it has been possible to control protein function by controlling subcellular localization, for example, by using ligand-induced dimerizers, including FKBP12 + FRB + rapamycin 7, 9 , pyrabactin resistance (PYR)/PYR1-like (PYL)/regulatory component + abscisic acid (ABA) + protein phosphatase type 2Cs (PP2Cs) 32 , and gibberellin insensitive (GAI) + gibberellin (GA3) + gibberellin insensitive dwarf1 (GID1) 33 . It has also been possible to control protein localization using light-induced dimerizers such as (LOV2) + GIGANTAE (GI) 34 , iLID + SsPB 35 , cryptochrome2 (CRY2) + cryptochrome interacting basic helix-loop-helix (CIB) 36 , or phytochrome B (PhyB) + phytochrome-interacting factor (PIF) 37 . These tools can be applied by attachment of the constitutively active form of the target protein to one part of the dimerizer and a localizing sequence to the other part. Alternatively, the protein can be trapped in an irrelevant subcellular region, to be reversibly released by light. Examples of this strategy include LOVTRAP, implemented using a 6-kDa engineered Z domain (Zdk) that interacts with LOV2 only in the dark state 38 , as well as LARIAT 39 and CRY2olig 40 , engineered to sequester target proteins as nonfunctional oligomers. Methods that rely on sterically blocking the active site include the PA-Rac1 approach described above [19] [20] [21] and control of the green fluorescent protein DRONPA 41 . The kinetics of activation and inactivation for different photoproteins can also be modulated according to the goals of the experiment. The LOV2 domain used here, which is activated in less than a millisecond, can be mutated to alter the half-life for return to the dark state from 2 to 496 s 38, 42 . An important advantage of the engineered allosteric control approaches described here is that they do not control protein activity by controlling localization. Rather, an intact analog of the target protein can be produced, with modifications away from the active site or other sites that bind to intracellular targets and control localization. Furthermore, light activation is rapid (<1 ms) and the kinetics of return to the dark state can be adjusted using specific point mutations 38 . The uniRapR and PI approaches require the identification of insertion sites, surface-exposed loops where the inserted domains will be allosterically coupled to the active site. Here, we describe an approach to identify insertion sites through computational screening, but in cases in which a protein has only a few surface loops, testing these empirically can suffice. A comprehensive empirical design strategy can also be pursued by creating random domain-insertion libraries with nuclease digestion, multiplex inverse PCR, and circular permutation 43 . Such an approach may identify additional sites not found by computational approaches, and is especially useful for proteins that can be tested in bacteria or yeast.
Limitations
For any given target protein, a robust approach to assay protein activity must be available. The protocol includes structure design, so a protein structure must be available or accessible via homology modeling. If a homology model must be built, and there is no close homolog structure available, the computational protocol described in Steps 1-8 cannot be applied. In that case, one can identify potential loop sites using sequence-based algorithms 44 . Finally, the approaches described in this protocol require a certain stability in the target protein. For some exceptionally unstable proteins, domain insertion will not be feasible.
The domain-insertion strategies described here are most effective for structures that include tight, short, surface-exposed loops connecting interacting structural units. These features may not be present in some proteins, such as transmembrane proteins without any intra-or extracellular structured domains, intrinsically disordered proteins, or unstable proteins (proteins with a folding free energy difference (ΔG U ) <~5 kcal/mol). However, for many proteins, solvent-accessible, evolutionarily nonconserved, and tight loops should be permissive for domain insertion, as the termini of uniRapR and LOV2 domains are in close proximity. For transmembrane proteins, the only practical option might be to insert the sensory domain into a non-transmembrane portion of the host protein.
There are inherent limitations of using light for protein control, including phototoxicity and the inaccessibility of some targets to light. For PA studies, it is important to measure the activity of the inactivated protein and to make sure that expression levels do not produce undesired biological effects before activation.
Experimental design
The Procedure has four sections: section 1 describes a computational strategy to identify the sites for domain insertion (Steps 1-7). Section 2 describes the molecular cloning steps to generate protein analogs containing iFKBP, uniRapR, or LOV2 as the sensory domain (Steps 8-13). Section 3 describes the testing of engineered proteins using in vitro assays (Step 14A and B) and an automated highcontent imaging assay (Step 14C). Section 4 describes a live-cell imaging assay performed on cells transfected with the engineered constructs, assessing the effects of allosteric regulation on various cell parameters (Steps 15-18). As proof-of-principle systems, we focus on kinases, Rho GEFs, and Rho GTPases. Src kinase and the GEF Vav2 were used as examples.
Identification of domain-insertion sites
Insertion sites must fulfill two important criteria. The domain insertion should not interfere with the folding and function of the target protein, and the perturbation induced by the uniRapR or LOV2 domains must effectively alter the active site. To this end, we recommend selecting 'tight loops' 1 that control the proximity of two internal structured units (e.g., the loop connects two parallel or antiparallel helices or strands, Fig. 3a ). These internal units can directly span the distance between the Fig. 3 | An approach to the design of allosteric protein switches. a, The 3D structure or a structural homolog of the target protein can be used to identify secondary structures, the surface exposure (Surface exp.) of each residue, and the contact map. By collecting homolog domain sequences from different species, sequence conservation (Seq. cons.) is calculated and used to identify surface sequences less likely to be important for function.
The insertion sites (shown with green asterisks) are tight surface loops connecting interacting elements of the interior secondary structure (e.g., two parallel strands or helices). b, The Src kinase domain (PDB ID 1Y57, shown on the right) is used as an example. The loop sites, along with other parameters, including solvent accessible area (SAA), sequence conservation (Cons), and contact map, were used to identify insertion sites (described in Steps 1-7). The vertical line shows the insertion site. The red arrow on the contact map and red sphere on the structure indicate the site that was selected for domain insertion in Src.
loop and the active site, or can contact a second structured unit that reaches the active site. This positioning of the insertion sites can lead to effective active site distortion by the uniRapR or LOV2 domains. The surface-exposed residues at the insertion site should not be important for the target protein's interactions, but should only play a role in holding together internal secondary structures. The sensory domain LOV2 or uniRapR alone should not sterically block important interactions between the target protein and its downstream ligand(s). Insertion into tight surface loops is possible, owing to the short distances between the termini of uniRapR and LOV2 (Fig. 3a) . Tight loops can often be simply selected by visual inspection of the protein structure, which can be obtained from the Protein Data Bank. When available, we also use data from the literature to exclude protein regions that are important for interaction with endogenous ligands.
Identification of domain-insertion sites from homology models
If no X-ray or NMR structure is available, a homology model of the structure can be built using tools such as I-Tasser 45 , Modeller 46 , and Rosetta 47 . Owing to its automatic pipeline algorithm, accuracy, and speed, we prefer I-Tasser for homology modeling. We identify the surface exposure of amino acids by computing the solvent accessible area (SAA) using Stride 48 , which can also provide the secondary structure information needed to select short loops. To identify sites where surface residues do not play important roles, we perform evolutionary sequence conservation analysis for each residue by collecting sequences of the protein portions targeted for modification (e.g., the catalytic domain) from all the available proteins and species in Pfam 49 . Although there are multiple ways to select the insertion sites, we recommend obtaining the domain sequences from Pfam 49 and feeding the Pfamderived sequence alignments to the online MISTIC server 50 . This server can perform multiple tasks, including sequence conservation analysis and co-evolution of surface residues and active site residues, to infer coevolution mapped on the protein structure and apply a sequence-based approach to detect the allosteric sites. By using a multiple sequence alignment (MSA) matrix, MISTIC provides Kullback-Liebler (KL) 50 conservation calculated from the frequency of a partition of amino acids in a sequence position and the background frequency of the amino acid in nature, obtained from the UniProt database.
Once the insertion loops are identified, multiple designs can be generated using alternative linkers to connect the inducible domain to the target domain. We generally insert the inducible domain into the middle of the insertion loop without any linker, with a linker consisting either of glycine, proline, and glycine (GPG) or glycine, serine, and glycine (GSG) residues. In initial designs, we recommend testing several possible linkers. If the protein is not fully active in the 'ON' state (activated state), the linker should be elongated with flexible residues (e.g., glycine and serine). If the protein shows some activity in the 'OFF' state (inactivated state), the linker should be shortened.
Picking the right strategy for allosteric regulation There are several critical points to be considered when deciding which protein control strategy to use. With analogs that can be photoinhibited, one must be aware of potential overexpression artifacts. Before irradiation, transfection of photoinhibitable analogs results in overexpression, and inhibition can restore endogenous protein levels. It is possible that in some cases, the cell will compensate for expression of the analog by downregulating the endogenous protein, but this is not always the case. When this does not happen, one might have to use a knockdown or knockout and rescue approach to replace the native gene. For analogs that are activatable, ideally, the protein analog will have little effect on cell function until it is activated. It can therefore be overexpressed and used to study the effects of activation with exact localization and/or timing. For PI-Vav2 and PI-Rac1, we compared overexpression of the analog to replacement of the endogenous protein; in both cases, PI produced changes in the cell's constitutive retraction or protrusion behavior, but the approach used affected the magnitude of the effects 1 . Activating the engineered protein with a ligand versus with light has distinct advantages and disadvantages. In our experience, rapamycin-induced activation has been very effective for inducing robust phenotypes, but activation is weakly reversible and cannot be focused on one subcellular region. Controlling protein activity with light by using the LOV domain provides much more rapid changes that can be localized, but it is harder to implement, especially deep within tissues. uniRapR can be photoactivated using a version of rapamycin caged with a photocleavable protecting group 51 . This enables rapid activation but does not provide the spatial resolution of LOV insertion. For protein analogs based on insertion of LOV2, it is possible to introduce mutations to tune the recovery kinetics of LOV2 (ref. 20 ). LOV2 can be activated rapidly, within less than a second. The half-life (t 1/2 ) is 1.7 s for the I427T mutant and 496 s for the V416L mutant, providing fast and slow recovery options 38 , respectively. The latter is useful for long-time-scale processes, in which the specimen need be irradiated for only less than a second every 8 min.
Testing whether proteins engineered for allosteric control respond to activation or inhibition One must be able to reliably test the activity and response of the engineered protein to activation or inhibition. For kinases, we have performed in vitro kinase assays using kinase immunoprecipitated from cell extracts to detect substrate phosphorylation (Step 14A). For Rho GEFs and GTPases, we have used co-immunoprecipitation assays 52 that report GEF-GTPase interactions (Step 14B), and assays based on Förster resonance energy transfer (FRET) biosensors 53 ( Step 14C). Option C should be selected only when appropriate biosensors are available. We quantify expression and the extent of pulldown using peptide tags such as myc and Flag fused to the target protein. In some cases, the terminus of a protein may be functionally important, so the tag location should be chosen carefully. For example, for Src kinase, we used a C-terminal myc tag, as myristoylation at the N terminus of Src is important for its localization. To increase the dynamic range and ensure that protein activity is under the control of the experimentalist, constitutively active mutant analogs (e.g., the Y527F mutant of Src kinase) and wild-type (WT) protein should be used as positive controls. As negative controls, cells expressing catalytically inactive mutants and cells not expressing engineered proteins should be included. Cells not expressing any of the constructs should also be included when testing the effect of induction itself on cellular signaling and cell behavior. Effects on motility can be readily monitored using the many published tools designed to quantify dynamic changes in cell shape and motility [54] [55] [56] .
Live imaging setup
For imaging studies, we recommend an open chamber or a perfusion system to deliver rapamycin into the cell medium. The microscope should be capable of irradiating at the excitation wavelengths of the fluorophores described and capable of switching between wavelengths used for LOV2 activation and visualization of the fluorophores used to tag the target protein. For LOV2-based optogenetic control, the excitation and emission wavelengths used for imaging fluorophores should be selected carefully, so that they do not overlap with the absorption wavelengths of LOV2. Because LOV2 is excited at 300-500 nm, we recommend using red fluorescent proteins, e.g., mCherry, or yellow fluorescent proteins, e.g., YPet or mVenus. For the yellow proteins, a 510-nm excitation filter with a sufficiently narrow bandwidth (e.g., Semrock FF-510/10) can be used to avoid LOV2 excitation. LOV2 is extremely sensitive to the blue light that is present in ambient light or from computer screens, so all the light sources nearby should be covered with high-pass yellow or red filters.
Materials Biological materials
The cell lines used in your research should be regularly checked to ensure that they are authentic and are not infected with mycoplasma.
• HEK293T cells (ATCC, cat. no. CRL-3216 or CRL-11268)
• HeLa cells (ATCC, cat. no. CCL-2)
• Engineered mouse embryonic fibroblasts (MEFs; Clontech, cat. no. 630914) that express a tetracycline element for doxycycline-off (tet-off) stable expression. This system ensures doxycyline-controlled expression of the transfected construct to avoid potential cellular toxicity due to overexpression
Reagents

Molecular cloning
• DNA encoding residues 1-198 of the uniRapR domain (Addgene, plasmid no. 45381). This plasmid is used to design single-chain rapamycin-induced allosteric proteins • DNA encoding residues 1-87 of the iFKBP domain (Addgene, plasmid no. 25933) and residues 1-96 of FRB (Addgene, plasmid no. 25920)
These plasmids are used to design dual-chain rapamycin-induced allosteric proteins • DNA encoding residues 1-143 of the LOV2 domain (Addgene, plasmid no. 86974). This plasmid is used to design photoactivatable (PA) or photo-inhibitable proteins • Plasmid vectors for transient mammalian cell expression, e.g., pTriex (Addgene, plasmid no. 66110) and pcDNA (Addgene, plasmid no. 52535)
• Plasmid vectors for viral infection, e.g., pBabe (Addgene, plasmid no. Biochemical GEF and GTPase activation assays • Bacterial expression plasmid to express mutant Rho GTPase such as pGEX-4T1-Rac1 G15A, pGEX-4T1-Cdc42 G15A, and pGEX-4T1-RhoA G17A (Addgene, plasmid nos. 69355, 69356, and 69357, respectively). These plasmids express GST-Rac1(G15A), GST-Cdc42(G15A), and GST-RhoA(G17A), respectively • Active GTPase pull-down assay kit for Rac1, Cdc42 pull-down assay kit, and RhoA pull-down assay kit (Cytoskeleton, cat. Live-cell imaging • 35-mm Glass-bottom dish (Mattek, cat. no. P35G-0.170-14-C) c CRITICAL The coating reagent of the coverslip may depend on the cellular process of interest. For migration studies, we use 5-μg/ml fibronectin (see Reagent setup section).
• Culture chambers (Attofluor Cell Chamber; Thermo Fisher Scientific, cat. no. A78167) • Microplates (MicroClear, 96-well; Sigma-Aldrich, cat. no. CLS3603-48EA)
• A fluorescence microscope with a 40×, 1.3-NA oil-immersion objective, and the ability to switch excitation and emission wavelengths (Olympus IX-81 with automated stage) c CRITICAL When using a mercury arc lamp, the microscope can be equipped with the following band-pass filters and dichroic mirrors: Chroma Technology, cat. nos. ET430/24× (for LOV2 illumination), ET572/35× (RFP excitation), and HQ620/60 M (RFP emission) (filters); Semrock, cat. nos. FF-520/15 (YFP excitation) and FF-565/24 (YFP emission) (filters); and Chroma Technology, cat. nos. 440/500/580 (for RFP) and T545LP (for YFP) (dichroic mirrors). The microscope should also be capable of adjusting irradiation intensity, in our case using neutral-density filters, e.g., with 1% transmittance.
Computational identification of insertion sites
• A 3D structure of the target protein domain (e.g., a crystal structure or a high-resolution (NMR structure Reagent setup c CRITICAL Unless stated otherwise, buffers can be stored at 4°C for up to 6 months. Where indicated, NaF, Na 3 VO 4 , DTT, and protease inhibitors should be added immediately before use.
Lysis buffer
Lysis buffer is 20 mM HEPES-KOH, pH 7.8, 50 mM KCl, 1 mM EGTA, 1% (vol/vol) NP-40, 1 mM NaF, 0.2 mM Na 3 VO 4 , and protease inhibitor according to the manufacturer's instructions.
Kinase reaction buffer
Kinase reaction buffer is 25 mM HEPES-KOH, pH 7.5, 5 mM MgCl 2 , 5 mM MnCl 2 , 0.5 mM EGTA, 0.005% (vol/vol) Brij-35 detergent, 1 mM NaF, and 0.1 mM Na 3 VO 4 .
Kinase wash buffer
Kinase wash buffer is 20 mM HEPES-KOH, pH 7.8, 50 mM KCl, 100 mM NaCl, 1 mM EGTA, and 1% (vol/vol) NP-40.
GEF bacterial lysis buffer GEF bacterial lysis buffer is 20 mM HEPES, pH 7.5, 150 mM NaCl, 5 mM MgCl 2 , 1% (vol/vol) Triton X-100, and 1 mM DTT, with protease inhibitors according to the manufacturer's instructions.
GEF bacterial wash buffer HBS GEF bacterial wash buffer HBS is 20 mM HEPES, pH 7.5, and 150 mM NaCl.
Purified paxillin-ATP mix
Purified paxillin-ATP mix is 0.1 mM ATP and 0.05 mg/ml paxillin in kinase reaction buffer. The paxillin-ATP mix should be freshly prepared. The GST-fused N-terminal domain of paxillin is purified as described in Lyons et al. 58 .
Procedure Computational identification of insertion sites • Timing 1-2 h
1 Go to UniProt (http://www.uniprot.org/) and obtain the UniProt ID and amino acid sequence of the target protein in FASTA format. For example, search 'Src' and click on 'P05480' for SRC_MOUSE. 2 Go to the Protein Data Bank (PDB) (https://www.rcsb.org) to check the availability of the target domain structure. For example, search for 'Src' and find a structure for its kinase domain, e.g., the PDB ID '6F3F' for mouse Src. Download the structure coordinates in PDB format. c CRITICAL STEP If the structure is not available, build a homology model for the target domain using I-Tasser as described in Roy et al. 57 (http://zhanglab.ccmb.med.umich.edu/I-TASSER/), which requires a FASTA sequence of the protein domain of interest and a subscription to the website. ? TROUBLESHOOTING 3 (Optional) Minimize the structural clashes using Chiron 59 at http://chiron.dokhlab.org by providing the .pdb file. Chiron identifies steric clashes in a protein structure on the basis of a clash score (derived from Van der Waals repulsion energy distributions of high-resolution structures), and removes the clashes through minimization by discrete molecular dynamics. 4 Go to Pfam (http://pfam.xfam.org) and enter the UniProt ID from Step 1 (P05480 for SRC_MOUSE) into the search box. In the resulting domain architecture schematic, select the target domain (e.g., 'Pkinase_Tyr'" for Src and click on it to obtain the Pfam ID PF07714 for the tyrosine kinase domains. 5 Go to the MISTIC web server (http://mistic.leloir.org.ar/index.php). Enter the Pfam ID (e.g., PF07714) and select a reference sequence (e.g., SRC_MOUSE) to upload the MSA matrix. An MSA matrix is uploaded by the server automatically once a Pfam ID is provided. Next, upload the .pdb file from Step 2 or 3 (either a .pdb structure such as 6f3f.pdb for the mouse Src tyrosine kinase domain downloaded from PDB or a homology model). This server will provide the sequence conservation (KL conservation) of each amino acid as a table or mapped to the protein structure. Plot the residue-KL value plot using a plot generator such as Excel. Mark all residues with a KL value <2 as nonconserved. An example for the Src kinase domain (residues 267-516) is provided in Fig. 3b . The insertion site should be selected from a loop that is not evolutionarily conserved. 6 Run Stride (download from http://webclu.bio.wzw.tum.de/stride/) using the following command from the terminal: stride protein_file.pdb -where protein_file.pdb is the .pdb file obtained in
Step 1. Use the kinase domain (residues 275-524) by selecting and saving the structure of this region in PyMOL. Stride will generate a list that includes a detailed secondary structure assignment, phi and psi angles of the tertiary structure, and the SAA. The output can be written as stride protein_file.pdb > output_file.txt. Plot the residue-SAA plot using a plot generator such as Excel. Mark the residues that have SAA values (the column name is -Area-, which are provided in the last column of the output text file) higher than 30 Å 2 . An example for the Src kinase domain is provided (Fig. 3b) . 7 Install and start CMView (http://www.bioinformatics.org/cmview), load the .pdb file from Step 1 and select 7 Å (the distance between two α-carbons) as a threshold for computing the contact map. CMView generates a 2D contact map. Select the tight loops that extend perpendicularly to the diagonal line. An example for the Src kinase domain is provided (Fig. 3b ). CMView will also start PyMOL, allowing you to visualize the tight loops (chosen using the guidelines described in this step) by selecting the relevant residues on the protein sequence to confirm that the loops are surface exposed.
Molecular cloning of the designed constructs • Timing 3-4 d
c CRITICAL The chemogenetic or optogenetic strategy to be pursued should be selected carefully (see 'Experimental design' section). For synthesis of photoactivatable rapamycin, detailed protocols are available in Karginov et al. 51 . 8 Design primers to amplify by PCR the sequence to be inserted into the designated site in the sequence encoding the target protein. Primers should be designed so that the resulting megaprimer (amplified insert) will have flanking ends that align to 25-30 bp on both sides of the insertion site of the target cDNA. In Fig. 4 , we illustrate the strategy for insertion of the iFKBP, uniRapR, or LOV2 domain into the target cDNA of interest (kinase, Rho GEF, or Rho GTPase, respectively). 9 To amplify the megaprimer insert, prepare the following PCR master mix on ice: The plasmids needed to generate these insert constructs are described in the 'Reagents' section. If using iFKBP and FRB, you will need to generate two separate megaprimers to insert each of these sequences into its respective target. 10 Amplify the insert, using the following conditions: 11 Run the entire PCR product on a 1% (wt/vol) agarose gel prepared with TAE buffer and gel-purify the resulting megaprimer using a Gel Extraction Kit. 12 Use 300-500 ng of the purified megaprimer and 50 ng of the target plasmid template to carry out site-directed mutagenesis as described in the QuikChange II kit. c CRITICAL STEP The target plasmid template will depend on what protein you are interested in regulating allosterically. Example target sequences used throughout this procedure are listed in the 'Reagents' section under the 'Kinase assay' and 'Biochemical GEF and GTPase activation assays' subheadings. 13 Sequence the cDNA of the constructs generated in Step 12 and amplify them using midi-or maxiprep kits (Qiagen) for transient transfection. The purified cDNA should be endotoxin free and the OD 260/280 ratio should be between 1.7 and 1.9. CRITICAL STEP Depending on the user's choice, the obtained cDNA can be subcloned into one of the vectors suitable for transient expression (pTriex or pcDNA; 'Reagents') or viral delivery (pBabe, pLenti, or FUW; 'Reagents'). j PAUSE POINT DNA can be stored at −20°C indefinitely.
Mammalian expression and activity tests
c CRITICAL The following steps in the Procedure detail how to test the activity of several types of engineered protein analogs. These tests are specific to the target proteins we chose to study: kinases, guanidine exchange factors, and GTPases. Therefore, the precise assay needed to test activity will depend on the target protein.
14 Proceed with option A to perform an in vitro kinase assay to test the activity of immunoprecipitated uniRapR or PI kinase using its purified substrate. Here, we provide an assay for Src kinase, but this procedure could be applied to other kinases. Follow option B for a Rho GEF or GTPase activity assay using co-immunoprecipitation, which enables the immunoprecipitation of the active GEF or GTPase from mammalian cell extracts using their binding partners as bait, or option C for using high-content microscopy to test the activity of engineered GEFs and GTPases with FRET biosensors in live cells. The high-content imaging assay enables rapid testing of biosensor activity in live cells transfected with increasing amounts of previously developed 60 GTPase biosensor and engineered constructs. A FRET sensor consists of a fluorescent donor (CFP) and acceptor (YFP) pair. Upon imaging cells at CFP, YFP, and FRET channels, the FRET/donor fluorescence ratio for each pixel or whole cell is used to assess the activity of the co-expressed construct. A detailed methods article describing how to perform the assay with GEFs and GTPases can be found in Slattery and Hahn (x) Incubate the lysates with the conjugated beads from Step 14A(v) at 4°C for 1.5-2 h on a rotating wheel. (xi) Centrifuge the beads at 3,000g for 2 min, at 4°C, then discard the supernatant and resuspend the beads in 500 μl of kinase wash buffer. Repeat twice for a total of three washes. (xii) Centrifuge the beads for 2 min at 3,000g, at 4°C. Resuspend the beads in 500 μl of kinase reaction buffer. Repeat twice. (xiii) Resuspend the beads in 40 μl of kinase reaction buffer; keep 20 μl for the kinase reaction in
Step 14A(xiv) and keep 20 μl for Western blot at −20°C. (xiv) Add 10 μl of substrate-ATP mix (e.g., purified paxillin-ATP mix to test Src activity; see 'Reagent setup' section) and immediately shake at 1,000 r.p.m. for 10 min at 37°C, using a heating 1.5-ml tube shaker. (xv) Stop the reaction by adding 30 µl of 2× Laemmli protein sample buffer, which should be equal to the sample volume. Denature these and the samples saved in Step 14A(ix and xiii) at 95°C for 5-10 min. Allow the samples to cool to room temperature (~25°C). (xvi) Perform Western blot 13 analysis using antibodies for phosphorylated and total substrate to test the activity of the kinase, anti-tag antibody to evaluate the amount of engineered protein, and a cellular marker as a loading control (e.g., vinculin, GAPDH). Assess whether the on/off activity of the designed construct is dependent on induction on the basis of the Western blot results. ? TROUBLESHOOTING (B) Testing the activity of engineered GEFs and GTPases with pull-down assays • Timing 4 d (i) If the target protein you have chosen to regulate allosterically is a GEF, transform BL21 cells with a GST-tagged mutant GTPase construct to test the engineered protein's activity in a GEF assay. If the target protein is a Rho GTPase, transform BL21 cells with a GTPase effector domain construct to test the engineered protein's activity in a GTPase assay. Follow the procedure described at https://www.neb.com/protocols/1/01/01/tra nsformation-protocol-for-bl21-de3-competent-cells-c2527 to carry out the transformations. Use GST-Rac1(G15A), GST-RhoA(T17A), and GST-Cdc42(G15A) ('Reagents'), which interact only with the active form of GEFs
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. Use GST-PDB, which can interact with active Rac1 and Cdc42, or GST-Rhotekin-RBD, which can interact with active RhoA. confluent, transfect with the designed uniRapR-or PI-GEF or PI-GTPase constructs or control (WT, constitutively active, and inactive mutant) constructs using Lipofectamine. In 100 µl of serum-free medium (per sample), mix the plasmids (500-2,000 µg) and Lipofectamine (~5 µl per microgram of DNA), and incubate for 15-20 min at room temperature. Then add 900 µl of serum-free medium on top of the transfection mix to make up the total volume to 1 ml. Remove and discard the medium from the cells, and add this 1 ml of diluted transfection mix gently to the cells. Return the cells that are in 1 ml of the diluted transfection mix to the incubator. After 4-6 h, add 1 ml of serum-free medium with 20% (vol/vol) FBS to make the final FBS concentration 10% in 2 ml. Incubate the cells overnight and replace the medium the next day with fresh DMEM supplemented with 10% (vol/vol) FBS. Grow the cells in an incubator overnight. To transfect HeLa cells with uniRapR-Src, follow the transfection protocol described in Step 14A(ii). To generate MEFs stably expressing PI-Src, first seed 3 million HEK293T cells in a 60-mm dish. Next, transfect these cells with a retrovirus plasmid, pBabe-PI-Src-mCherry, and a packaging plasmid, pcl-eco, using Lipofectamine reagents and following the manufacturer's recommendations. Change the medium the next day. 24-48 h after the medium change, collect the medium, filter with a 0.45-μM filter to remove the cells, and add the virus-containing medium to the 10-cm dish that has the MEFs (~50% confluent). 2-3 d after this transduction step, add puromycin to the cell medium to eliminate the uninfected cells. After the antibiotic selection, seed the cells sparsely onto a 35-mm glass-bottom dish coated with 5 μg/ml fibronectin in DMEM supplemented with 10% (vol/vol) FBS. c CRITICAL STEP If a doxycycline-inducible system (tet-off) is used, doxycycline (0.5-1 µg/ml) should be kept in the medium until the cells attach to the dish. Then the medium should be exchanged for doxycycline-free medium two times and the dish should be covered with aluminum foil to avoid ambient light. c CRITICAL STEP If there will be a transfection the next day with the photosensitive constructs, the samples should be covered with aluminum foil. To image transiently transfected HeLa cells, uniRapR-Src-Cer-myc with a cell membrane marker ('Reagents') can be used. Follow the transfection protocol described in Step 14A(ii). 16 Before imaging, warm the L15 Leibovitz medium supplemented with 5% (vol/vol) FBS and 10 mM HEPES to 37°C in a water bath. Mount the coverslips in a chamber suitable for live-cell imaging. c CRITICAL STEP Work under red light for blue light−sensitive samples. Add warm imaging medium (2 ml for a 35-mm imaging dish). c CRITICAL STEP Keep the samples away from any light sources that include blue light wavelengths, such as computer screens or ambient light. A filter on the computer screen and ambient light source to block the light at a wavelength of <500 nm can be used, but simply using a red light bulb can suffice. The computer can be kept far from the microscope stage or a 'tent' of foil or paper can be built over the sample on the stage. c CRITICAL STEP Addition of HEPES is important to maintain the appropriate pH of the medium, which is essential for cell health. ? TROUBLESHOOTING 17 Image the cells at CFP wavelengths (excitation at~430 nm and emission at~470 nm) to monitor uniRapR-Src tagged with Cerulean (Cer). If a PI construct is expressed, LOV2 can be illuminated using GFP excitation settings (400-500 nm, see 'Live-cell imaging' in the 'Equipment' section). Take images every 10-30 s for 90 min to monitor spontaneous cell motility. For rapamycinsensitive samples, add 100-500 nM rapamycin or its analog (non-immunosuppressive analogs such as 1-5 μM iRap 7 or 20-40 μM AP21967) after obtaining sufficient images to establish a baseline. For example, for HeLa cells expressing uniRapR-Src, cells were imaged for 30 min before addition of rapamycin. Then cells were imaged for 1-2 h after addition of rapamycin to the medium. c CRITICAL STEP If transmitted light is used for imaging, a long-pass red filter should be used to avoid LOV2 activation. 18 Analyze the images using MATLAB modules 54, 55 . Individual .tiff files of the HeLa cells expressing uniRapR-Src-Cer-myc imaged every 30 s are collected and used first for background subtraction and masking using the program MovThresh 54, 55 . 
PROTOCOL NATURE PROTOCOLS
Troubleshooting
Troubleshooting advice can be found in Table 1 .
Timing
Steps 1-7, computational identification of insertion sites: 1-2 h Steps 8-13, molecular cloning of the designed constructs: 3-4 d
Step 14A(i-xvi), testing of inducible kinase activity in vitro: 4 d
Step 14B(i-x), testing the activity of engineered GEFs and GTPases with pull-down assays: 4 d
Step 14C(i-v), high-content live-cell imaging: 3 d Steps 15-18, live-cell imaging and image processing: 3 d
Anticipated results
We have provided guidelines for the design of proteins that can be allosterically regulated by rapamycin or blue light. The guidelines should help to identify sites for insertion of iFKBP, uniRapR, and LOV2 domains. If the target protein is a kinase, a Rho GEF, or a Rho GTPase, these guidelines should also provide an approach for testing the activity of the engineered target protein. Both in vitro and in living cells, the stimulus (rapamycin or light) should induce no change in the activity of the expressed proteins when no domain has been inserted. The constructs that have the inserted domain, but also bear an inactivating mutation, should also not respond to rapamycin or blue light. A set of anticipated results is presented in Fig. 6 . In one example, myc-tagged Src and Src-uniRapR were immunoprecipitated from HEK293T extracts prepared from cells overexpressing these proteins and incubated with rapamycin or vehicle. The protein was then incubated with a purified Src substrate (paxillin) in vitro with rapamycin or vehicle, and substrate phosphorylation was monitored using a phosphopaxillin antibody (Fig. 6a, left) . In another example, PI-Src activity was tested by immunoprecipitating Src and monitoring its substrate FAK using a phospho-FAK antibody (Fig. 6a, right) . PI-Src activity was also tested by monitoring cell motility in the absence and presence of light (Fig. 6a,  bottom) . In the representative cell images, PI-Src-mCherry in the cell localizes to the focal adhesions upon light absorption, resulting in cell migration. With some constructs, one might find 'leakiness' (activity in the 'OFF' state) or less than native activity when activation is induced. To overcome this, optimization of linkers is usually important, and some insertion sites will be better than others. The effects of linkers are shown in Fig. 6b . A set of uniRapR-PAK constructs with different linkers were expressed in HEK293T cells. The cells were incubated with or without rapamycin, and phosphorylation of the PAK1 substrate MEK1 was monitored using a phospho-MEK antibody. If substantial activity is observed in the 'OFF' state of a uniRapR protein or in a PI protein upon light treatment, the linkers between the sensory and the host domain should be shortened. If insufficient activity is observed in the 'ON' state of the uniRapR protein or in the dark state of the PI protein, the linkers between the sensory and the host domain should be elongated, or another insertion site should be tested. The same strategy should be pursued if there is lower expression of the constructs compared with controls. Some level of leakiness can be tolerated, depending on the biology and expression levels of the endogenous proteins. For activatable analogs, reduced maximal activation is more desirable than leakiness, as one can express more of the protein to achieve the desired level of activity in the 'ON' state. For example, A291GPG for RapR-PAK1 and L1 for uniRapR-PAK1 show leaky activity in the 'OFF' state, whereas 289/293GPG for RapR and L2(v2) for uniRapR are only active in the 'ON' state (Fig. 6b) . For photoinhibited proteins, the trade-off is less clear and will depend on the experiment. The control with uniRapR should provide full activity with rapamycin and no activity without rapamycin. Conversely, in photo-inhibitable constructs, the protein should be deactivated with light. uniRapR-Src is deactivated without rapamycin, and the activity is rescued with rapamycin. A constitutively active (Src Y527F or YF) protein is used as a positive control, whereas a catalytically inactive (kinase dead or KD) mutant is used as a negative control. The expression levels of the constructs are compared by blotting myc or GFP, which are fused to the constructs. Paxillin and focal adhesion kinase (FAK) are Src substrates. DM and LM denote dark and lit mutants, respectively. (Bottom) An alternative method such as live-cell imaging should also be used to test the engineered constructs. In this case, the motility of mouse embryonic fibroblasts (MEFs) and translocation of PI-Src to focal adhesions are monitored upon PI of PI-Src. Scale bars, 20 μm. b, (Left) The crystal structure of the PAK1 insertion loop. (Right) The RapR-PAK1 (top) and uniRapR-PAK1 (bottom) constructs were expressed in HEK293T cells, and cells were incubated with rapamycin or vehicle for an hour the day after the transfections. The activities of the constructs were evaluated with Western blotting using the phosphorylated form of MEK1, a PAK1 substrate. The expression levels of the constructs are compared by blotting GFP or mCherry, which are fused to the constructs. In another case, uniRapR-PAK1 was generated by inserting the uniRapR domain into a different loop (uniRapR-PAK1-L2). a adapted with permission from ref. 1 , American Association for the Advancement of Sciences, and ref. 13 , National Academy of Sciences. b adapted with permission from ref. 1 , American Association for the Advancement of Sciences, and ref. 11 , American Chemical Society.
